Next 10 |
home / stock / iqaif / iqaif news
(NewsDirect) Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblasto...
--News Direct-- Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring gliob...
MILWAUKEE, WI / ACCESSWIRE / July 13, 2023 / Imaging Biometrics, LLC (IB) , a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI)(OTCQB:IQAIF) , today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of p...
MILWAUKEE, WI / ACCESSWIRE / February 28, 2023 / IQ-AI Limited, (OTCQB:IQAIF)(LSE:IQAI) , and its US-based subsidiary, Imaging Biometrics, LLC (Milwaukee, WI) is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for ga...
Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams MILWAUKEE, WI / ACCESSWIRE / May 31, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI) , today announced it has submitted an FDA ...
Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue MILWAUKEE, WI / ACCESSWIRE / May 3, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF)(LSE:IQAI) , notes a recent study published in the American Journal of Neuroradiology entitled: ...
Innovative Therapy that "Tricks" and Destroys Cancer Cells Advances to Clinical Trial PR Newswire Results from pre-clinical research show iron-like compound holds promise for treating patients with glioblastoma, an aggressive brain cancer MILWAUKEE , Apri...
MILWAUKEE, WI / ACCESSWIRE / March 10, 2022 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is open for enrollment. The trial is being led by Dr. Jennifer Connelly, MD, Associate Professor of Neurology...
Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated MILWAUKEE, WI / ACCESSWIRE / March 7, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI), is pleased to announce the publication of a review authored by Internatio...
Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI), discusses its most successful year on record. Increases technology platform and expects record revenues Rolls out Phase I clinical trial and prepares to file 510(K) with the FDA MILWAUKEE, WI / ACCESS...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblasto...
--News Direct-- Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring gliob...
MILWAUKEE, WI / ACCESSWIRE / July 13, 2023 / Imaging Biometrics, LLC (IB) , a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI)(OTCQB:IQAIF) , today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of p...